StockNews.AI
MGRM
StockNews.AI
36 days

MGRM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Monogram Technologies to Zimmer Biomet

1. Monogram agreed to sell to Zimmer Biomet for $4.04 per share. 2. Sale includes potential CVR up to $12.37 per share based on milestones. 3. Investors expressed disappointment over the sale price on SeekingAlpha. 4. An investigation will assess if the sale price is fair. 5. Concerns raised about disclosure of transaction-related information.

4m saved
Insight
Article

FAQ

Why Bearish?

Investor dissatisfaction with the sale price suggests future price volatility. Historical examples show such reactions can negatively impact stock prices.

How important is it?

The investigation highlights serious concerns that could derail the sale, impacting stock price. Stakeholders may take action based on perceived fairness of the deal.

Why Short Term?

Immediate investor reactions may lead to market fluctuations soon after the announcement. Past transactions with similar investor sentiments usually affect stocks quickly.

Related Companies

ZBHABMDSYK
MONSEY, N.Y., July 14, 2025 (GLOBE NEWSWIRE) --  The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030. At least two investors have already expressed extreme disappointment in the sale price on SeekingAlpha. If you remain a Monogram shareholder and have concerns about the proposed sale, you may contact our firm at the following link to discuss your legal rights at no charge: https://wohlfruchter.com/cases/monogram-technologies/ Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com. Why is there an investigation?On July 14, 2025, Monogram announced that it had agreed to be sold to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable CVR entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030. At least two investors have expressed disappointment in the sale price on SeekingAlpha with one investor complaining, “Too cheap!,” and another responding that “I am not very happy about it either.” “We are investigating whether the Monogram Board of Directors acted in the best interests of Monogram shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Monogram shareholders, as well as whether all material information regarding the transaction has been fully disclosed.” About Wohl & Fruchter Wohl & Fruchter LLP has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners. Contact:Wohl & Fruchter LLPJoshua E. Fruchter Toll Free 866.833.6245alerts@wohlfruchter.com www.wohlfruchter.com

Related News